Obesity Clinical Trial
Official title:
Normalization of Vitamin D Levels and Its Effect on Glucose Homeostasis in Obese Youth
Vitamin D deficiency is extremely common in obese youth. In our obese population followed in
the Endocrinology clinic at Children's Medical Center Dallas, vitamin D levels were inversely
correlated with a measure of insulin resistance. We propose to show that correction of
vitamin D levels in obese children and adolescents improves their insulin sensitivity. Obese
youth presenting to the Center for Obesity and its Consequences on Health (COACH) clinic will
be randomized to receive either the most recent Institute of Medicine (IOM) recommendations
of minimum D3 dose of 600 IU/day (1), or receive higher doses of D3 such that the blood
levels of vitamin D will be brought to a target level in either the low part or high part of
the normal range. The goal is to determine if correction of vitamin D deficiency will improve
insulin sensitivity in this group. Secondary goals include determining whether correction of
vitamin D deficiency in obese adolescents and children results in less weight gain, and
determining the amount of D3 required to correct vitamin D levels in this population.
Our specific hypotheses are as follows:
Hypothesis #1 Obese youth treated with Vitamin D3 who achieve low-normal 25-hydroxyvitamin D3
(OHD) levels (30-50 ng/mL) or high-normal 25-OHD levels (60-80 ng/mL) will have improved
insulin resistance, as measured by Homeostatic Model Assessment of Insulin Resistance
(HOMA-IR), compared to those individuals with deficient 25-OHD levels (< 30 ng/mL).
Hypothesis #2 Subjects with a higher BMI will have higher Vitamin D dose requirements than
current IOM recommendations of 600 IU/day and will take a longer period of time to reach
target 25-OHD levels.
Hypothesis #3 Subjects with normal 25-OHD levels will demonstrate less weight gain compared
to subjects on the control arm.
Concise Summary of Project: The proposed study is a prospective, unblinded dose-ranging trial
to examine in obese youth 1) the effect of correcting Vitamin D (Vit D) deficiency on insulin
resistance, 2) the effect of correcting Vit D deficiency on weight gain, and 3) the amount of
Vit D3 required to achieve Vit D sufficiency in obese adolescents. Subjects will be recruited
from obese children and adolescents aged 6 to 17 years presenting to the COACH clinic, a
referral clinic for obese children at Children's Medical Center of Dallas. Approximately 1300
new patients are seen in the COACH clinic each year. Ethnicity will be self-assigned as
African-American, Caucasian, Hispanic, or Other. The ethnic makeup of the COACH clinic over
the last 20 months was as follows: African-American 25%, Caucasian 19.5%, Hispanic 52%, and
Other 3.5%.
As per standard practice in the COACH clinic, a height (cm), weight (kg), and blood pressure
will be obtained, and body mass index (kg/m2) calculated for each patient. Fasting total
cholesterol, LDL, HDL, triglyceride, 25-OHD, Hemoglobin A1c (A1c), and fasting insulin will
be obtained, and an Oral Glucose Tolerance Test (OGTT) performed. The baseline estimate of
insulin sensitivity is calculated from the fasting insulin and glucose values, and reported
as the HOMA-IR. After Informed Consent has been obtained, participants will be randomized to
either the Control group (5000 IU/wk), the Low-normal 25-OHD group (target 25-OHD 30-50
ng/mL), or the High-normal 25-OHD group (target 25-OHD 60-80 ng/mL). A 25-OHD < 25 ng/mL will
be confirmed. These groups will be matched for age (6-12 years versus 13-17 years) and
ethnicity (Caucasian versus African-American verus Hispanic). Approximately 60 patients will
be recruited for each group. Subject participation will continue until Vit D sufficiency has
been documented for 4 consecutive months, at which point the fasting insulin and glucose
values will be repeated for calculation of HOMA-IR and assessment of insulin sensitivity, and
amount of weight gain will be measured.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |